PL1781649T3 - Podstawione hydantoiny - Google Patents

Podstawione hydantoiny

Info

Publication number
PL1781649T3
PL1781649T3 PL05771890T PL05771890T PL1781649T3 PL 1781649 T3 PL1781649 T3 PL 1781649T3 PL 05771890 T PL05771890 T PL 05771890T PL 05771890 T PL05771890 T PL 05771890T PL 1781649 T3 PL1781649 T3 PL 1781649T3
Authority
PL
Poland
Prior art keywords
substituted hydantoins
hydantoins
substituted
Prior art date
Application number
PL05771890T
Other languages
English (en)
Inventor
Xin-Jie Chu
Nader Fotouhi
Nicholas John Silvester Huby
Norman Kong
Lee Apostle Mcdermott
John Anthony Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1781649T3 publication Critical patent/PL1781649T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL05771890T 2004-08-17 2005-08-09 Podstawione hydantoiny PL1781649T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20
EP05771890A EP1781649B1 (en) 2004-08-17 2005-08-09 Substituted hydantoins
PCT/EP2005/008633 WO2006018188A2 (en) 2004-08-17 2005-08-09 Substituted hydantoins

Publications (1)

Publication Number Publication Date
PL1781649T3 true PL1781649T3 (pl) 2009-01-30

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05771890T PL1781649T3 (pl) 2004-08-17 2005-08-09 Podstawione hydantoiny

Country Status (16)

Country Link
US (1) US7427635B2 (pl)
EP (1) EP1781649B1 (pl)
JP (1) JP4927733B2 (pl)
KR (2) KR20090006885A (pl)
AR (1) AR050297A1 (pl)
AT (1) ATE404556T1 (pl)
AU (1) AU2005274390B2 (pl)
BR (1) BRPI0514515A (pl)
CA (1) CA2576599A1 (pl)
DE (1) DE602005008986D1 (pl)
ES (1) ES2313389T3 (pl)
MX (1) MX2007001846A (pl)
PL (1) PL1781649T3 (pl)
RU (1) RU2383542C2 (pl)
TW (1) TW200621764A (pl)
WO (1) WO2006018188A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
ATE551336T1 (de) 2007-08-16 2012-04-15 Hoffmann La Roche Substituierte hydantoine
BRPI0820696A2 (pt) * 2007-12-20 2019-09-24 Hoffmann La Roche hidantoínas substituídas como inibidores de cinase de mek
WO2010074776A2 (en) 2008-06-16 2010-07-01 The University Of Tennessee Research Foundation Compounds for the treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
KR20130100903A (ko) 2010-04-28 2013-09-12 바이엘 크롭사이언스 아게 살진균제로서의 케토헤테로아릴피페리딘 및 케토헤테로아릴피페라진 유도체
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
MX2021002456A (es) * 2018-09-17 2021-06-15 Yungjin Pharmaceutical Co Ltd Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables.
JP2023517106A (ja) * 2020-03-13 2023-04-21 ユンジン ファーム．カンパニー、リミテッド チアゾール誘導体またはその薬学的に許容される塩を含む癌の予防または治療用薬学組成物
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JP2002511092A (ja) 1997-07-01 2002-04-09 ワーナー−ランバート・コンパニー ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
DE60113247T2 (de) * 2000-05-03 2006-06-22 F. Hoffmann-La Roche Ag Hydantoin-enthaltende glucokinase aktivatoren
BR0211265A (pt) * 2001-07-19 2004-07-20 Pharmacia Italia Spa Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor

Also Published As

Publication number Publication date
AU2005274390B2 (en) 2012-01-19
US20060041146A1 (en) 2006-02-23
ATE404556T1 (de) 2008-08-15
JP4927733B2 (ja) 2012-05-09
US7427635B2 (en) 2008-09-23
ES2313389T3 (es) 2009-03-01
WO2006018188A2 (en) 2006-02-23
AR050297A1 (es) 2006-10-11
MX2007001846A (es) 2007-03-28
AU2005274390A1 (en) 2006-02-23
WO2006018188A3 (en) 2006-05-18
CA2576599A1 (en) 2006-02-23
EP1781649A2 (en) 2007-05-09
TW200621764A (en) 2006-07-01
JP2008509950A (ja) 2008-04-03
EP1781649B1 (en) 2008-08-13
BRPI0514515A (pt) 2008-06-10
RU2383542C2 (ru) 2010-03-10
KR20070034635A (ko) 2007-03-28
DE602005008986D1 (de) 2008-09-25
KR100889721B1 (ko) 2009-03-23
RU2007109651A (ru) 2008-09-27
KR20090006885A (ko) 2009-01-15

Similar Documents

Publication Publication Date Title
IL205159A0 (en) Imidazole compounds
IL181732A0 (en) 2-morpholino-4-pyrimidone compound
IL187279A0 (en) Hydantoin compounds
PL1781649T3 (pl) Podstawione hydantoiny
GB0415663D0 (en) Compound
EP1732560A4 (en) SUBSTITUTED CINNOLINE-4-YLAMINE
IL180888A0 (en) Substituted n-acyl-2-aminothiazoles
GB0408771D0 (en) Compound
GB0405193D0 (en) Compounds
IL178208A0 (en) Novel imidazoles
GB0401269D0 (en) Compounds
GB0421106D0 (en) Compound
GB0405101D0 (en) Compounds
GB0408772D0 (en) Compounds
ZA200700723B (en) Substituted N-acyl-2-aminothiazoles
GB0425969D0 (en) Compound
GB0411562D0 (en) Compound
GB0403593D0 (en) Compounds
GB0428295D0 (en) Compound
GB0403595D0 (en) Compounds
ZA200703075B (en) Imidazole compound
GB0419315D0 (en) Compounds
GB0405198D0 (en) Compounds
GB0405194D0 (en) Compounds
GB0401657D0 (en) Compounds